Review Article | Published:

Global epidemiology of hyperthyroidism and hypothyroidism

Nature Reviews Endocrinology volume 14, pages 301316 (2018) | Download Citation

Abstract

Thyroid hormones are essential for growth, neuronal development, reproduction and regulation of energy metabolism. Hypothyroidism and hyperthyroidism are common conditions with potentially devastating health consequences that affect all populations worldwide. Iodine nutrition is a key determinant of thyroid disease risk; however, other factors, such as ageing, smoking status, genetic susceptibility, ethnicity, endocrine disruptors and the advent of novel therapeutics, including immune checkpoint inhibitors, also influence thyroid disease epidemiology. In the developed world, the prevalence of undiagnosed thyroid disease is likely falling owing to widespread thyroid function testing and relatively low thresholds for treatment initiation. However, continued vigilance against iodine deficiency remains essential in developed countries, particularly in Europe. In this report, we review the global incidence and prevalence of hyperthyroidism and hypothyroidism, highlighting geographical differences and the effect of environmental factors, such as iodine supplementation, on these data. We also highlight the pressing need for detailed epidemiological surveys of thyroid dysfunction and iodine status in developing countries.

Key points

  • Thyroid disease is a global health problem that can substantially impact well-being, particularly in pregnancy and childhood.

  • In advanced economies, the prevalence of undiagnosed thyroid disease is falling owing to widespread thyroid function testing and relatively low thresholds for treatment initiation.

  • Iodine nutrition remains a key determinant of thyroid function worldwide, and continued vigilance against the resurgence of iodine deficiency in previously sufficient regions remains essential.

  • More studies are needed in developing countries, especially within Africa, to understand the role of ethnicity and iodine nutrition fluxes in current disease trends.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Ontogeny, anatomy, metabolism and physiology of the thyroid. Thyroid Disease Manager (2011).

  2. 2.

    , & Hyperthyroidism. Lancet 388, 906–918 (2016).

  3. 3.

    , , & Hypothyroidism. Lancet 390, 1550–1562 (2017).

  4. 4.

    , , , & Welsh-sparing dysphasia. Lancet 382, 1608 (2013).

  5. 5.

    et al. Weekly intramuscular injection of levothyroxine following myxoedema: a practical solution to an old crisis. Case Rep. Endocrinol. 2015, 169194 (2015).

  6. 6.

    Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J. Clin. Endocrinol. Metab. 97, 3068–3078 (2012).

  7. 7.

    et al. The relationship between TSH and free T4 in a large population is complex and nonlinear and differs by age and sex. J. Clin. Endocrinol. Metab. 98, 2936–2943 (2013).

  8. 8.

    et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur. Thyroid J. 2, 215–228 (2013).

  9. 9.

    Iodine deficiency. Endocr. Rev. 30, 376–408 (2009).

  10. 10.

    The epidemiology of thyroid disease. Br. Med. Bull. 99, 39–51 (2011).

  11. 11.

    et al. Identification of novel genetic loci associated with thyroid peroxidase antibodies and clinical thyroid disease. PLoS Genet. 10, e1004123 (2014).

  12. 12.

    et al. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999–2002). Thyroid 17, 1211–1223 (2007).

  13. 13.

    et al. Low prevalence of hypothyroidism among black and Mulatto people in a population-based study of Brazilian women. Clin. Endocrinol. 66, 803–807 (2007).

  14. 14.

    et al. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 97, 2543–2565 (2012).

  15. 15.

    Smoking and thyroid. Clin. Endocrinol. 79, 145–151 (2013).

  16. 16.

    Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol. Metab. 31, 213–222 (2016).

  17. 17.

    , , & Thyroid hormone signaling during early neurogenesis and its significance as a vulnerable window for endocrine disruption. Biochim. Biophys. Acta 1849, 112–121 (2015).

  18. 18.

    et al. Serum selenium is low in newly diagnosed Graves' disease: a population-based study. Clin. Endocrinol. 79, 584–590 (2013).

  19. 19.

    et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am. J. Med. 123, 183.e1–183.e9 (2010).

  20. 20.

    , & Characterization of thyroid abnormalities in a large cohort of children with Down syndrome. Hormone Res. Paediatr. 87, 170–178 (2017).

  21. 21.

    et al. Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin. Endocrinol. 61, 494–502 (2004).

  22. 22.

    , , & Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386, 461–468 (2015).

  23. 23.

    et al. Iodine intake as a determinant of thyroid disorders in populations. Best practice and research. Clin. Endocrinol. Metab. 24, 13–27 (2010).

  24. 24.

    et al. Investigation of thyroid dysfunction is more likely in patients with high psychological morbidity. Fam. Pract. 29, 163–167 (2012).

  25. 25.

    et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern. Med. 174, 32–39 (2014).

  26. 26.

    , , & The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 923–931 (2014).

  27. 27.

    et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002).

  28. 28.

    et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin. Endocrinol. 7, 481–493 (1977).

  29. 29.

    , , & Graves' disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin. Proc. 45, 636–644 (1970).

  30. 30.

    et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. 43, 55–68 (1995).

  31. 31.

    , & Increased incidence of thyrotoxicosis in Malmo during the years 1988–1990 as compared to the years 1970–1974. J. Intern. Med. 239, 57–62 (1996).

  32. 32.

    , & Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005. Clin. Endocrinol. 78, 768–776 (2013).

  33. 33.

    et al. Comparative study of thyroid function and types of thyroid dysfunction in two areas in Denmark with slightly different iodine status. Eur. J. Endocrinol. 143, 485–491 (2000).

  34. 34.

    et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur. J. Endocrinol. 143, 639–647 (2000).

  35. 35.

    et al. Screening for thyroid diseases in an iodine sufficient area with sensitive thyrotrophin assays, and serum thyroid autoantibody and urinary iodide determinations. Clin. Endocrinol. 38, 273–281 (1993).

  36. 36.

    Managing thyroid disease in general practice. Med. J. Aust. 205, 179–184 (2016).

  37. 37.

    et al. Five-year incidence and progression of thyroid dysfunction in an older population. Intern. Med. J. 40, 642–649 (2010).

  38. 38.

    , , & High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area versus high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J. Intern. Med. 229, 415–420 (1991).

  39. 39.

    et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur. J. Endocrinol. 155, 219–228 (2006).

  40. 40.

    et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J. Clin. Endocrinol. Metab. 84, 561–566 (1999).

  41. 41.

    et al. Iodine deficiency and excess coexist in china and induce thyroid dysfunction and disease: a cross-sectional study. PLOS ONE 9, e111937 (2014).

  42. 42.

    et al. Prevalence of thyroid dysfunction with adequate and excessive iodine intake in Hebei Province, People's Republic of China. Public Health Nutr. 18, 1692–1697 (2015).

  43. 43.

    Impact of iodination on thyroid pathology in Africa. J. R. Soc. Med. 99, 396–401 (2006).

  44. 44.

    & Epidemiology of thyroid diseases in Africa. Indian J. Endocrinol. Metabolism 15, S82–S88 (2011).

  45. 45.

    , & Thyroid dysfunction in the elderly. South Afr. Med. J. 87, 1119–1123 (1997).

  46. 46.

    Thyrotoxicosis in urban black Africans: a rising incidence. East Afr. Med. J. 58, 109–116 (1981).

  47. 47.

    , , & Spectrum of Endocrine Disorders in Central Ghana. Int. J. Endocrinol. 2017, 7 (2017).

  48. 48.

    , , & Thyroid Disorders in Central Ghana: The Influence of 20 Years of Iodization. J. Thyroid Res. 2017, 8 (2017).

  49. 49.

    & Cardiovascular involvement in patients with different causes of hyperthyroidism. Nature reviews. Endocrinology 6, 431–443 (2010).

  50. 50.

    , & Pattern of thyroid disorders in the southwestern region of Nigeria. Ethn. Dis. 17, 327–330 (2007).

  51. 51.

    , & Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin. Endocrinol. 36, 291–294 (1992).

  52. 52.

    et al. The association of periodic paralysis and hyperthyroidism in Japan. J. Clin. Endocrinol. Metab. 17, 1454–1459 (1957).

  53. 53.

    , , , & Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. Arch. Intern. Med. 149, 2597–2600 (1989).

  54. 54.

    et al. HLA and thyrotoxic periodic paralysis in Japanese patients. J. Clin. Endocrinol. Metab. 64, 1075–1078 (1987).

  55. 55.

    & Extrathyroidal manifestations of Graves' disease: a 2014 update. J. Endocrinol. Invest. 37, 691–700 (2014).

  56. 56.

    et al. The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J. Endocrinol. Invest. 39, 1445–1451 (2016).

  57. 57.

    et al. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br. J. Ophthalmol. 99, 1531–1535 (2015).

  58. 58.

    , , & Toxic multinodular goiter in the elderly. J. Endocrinol. Invest. 25, 16–18 (2002).

  59. 59.

    , & Thyroiditis. N. Engl. J. Med. 348, 2646–2655 (2003).

  60. 60.

    , , , & Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch. Intern. Med. 140, 478–482 (1980).

  61. 61.

    Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol. Metab. Clin. North Am. 27, 169–185 (1998).

  62. 62.

    et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27, 315–389 (2017).

  63. 63.

    , , , & Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J. Clin. Endocrinol. Metab. 88, 2100–2105 (2003).

  64. 64.

    , , & Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies. Scand. J. Clin. Lab. Invest. 73, 240–244 (2013).

  65. 65.

    & Silent (painless) thyroiditis. Evidence of a geographic variation in frequency. Arch. Intern. Med. 145, 473–475 (1985).

  66. 66.

    Silent thyroiditis. Arch. Intern. Med. 143, 2214 (1983).

  67. 67.

    , , & The effects of amiodarone on the thyroid. Endocr. Rev. 22, 240–254 (2001).

  68. 68.

    , , , & Amiodarone and the thyroid: a 2012 update. J. Endocrinol. Invest. 35, 340–348 (2012).

  69. 69.

    & Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data. Endokrynol. Polska 63, 2–9 (2012).

  70. 70.

    & Amiodarone-induced thyrotoxicosis: a review. Can. J. Cardiol. 25, 421–424 (2009).

  71. 71.

    et al. Prevalence of amiodarone-induced thyrotoxicosis and associated risk factors in Japanese patients. Int. J. Endocrinol. 2014, 534904 (2014).

  72. 72.

    , , & Endocrine side effects of cancer immunotherapy. Endocr. Relat. Cancer 24, T331–T347 (2017).

  73. 73.

    et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4, 173–182 (2018).

  74. 74.

    et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J. Clin. Endocrinol. Metab. 99, 80–89 (2014).

  75. 75.

    , , & Management of endocrine disease: subclinical thyrotoxicosis: prevalence, causes and choice of therapy. Eur. J. Endocrinol. 176, R325–R337 (2017).

  76. 76.

    , , & The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J. Clin. Endocrinol. Metab. 96, E1–E8 (2011).

  77. 77.

    et al. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin. Endocrinol. 77, 146–151 (2012).

  78. 78.

    Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin. Endocrinol. 72, 685–688 (2010).

  79. 79.

    et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 8, 83–100 (1998).

  80. 80.

    & Iodine excess and hyperthyroidism. Thyroid 11, 493–500 (2001).

  81. 81.

    et al. A review: Radiographic iodinated contrast media-induced thyroid dysfunction. J. Clin. Endocrinol. Metab. 100, 376–383 (2015).

  82. 82.

    & Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 1, 238–249 (2013).

  83. 83.

    , , & Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat. Rev. Endocrinol. 13, 610–622 (2017).

  84. 84.

    et al. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid 23, 758–765 (2013).

  85. 85.

    , , & Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study. J. Clin. Endocrinol. Metab. 100, 1164–1171 (2015).

  86. 86.

    & Important considerations in the management of Graves' disease in pregnant women. Expert Rev. Clin. Immunol. 11, 947–957 (2015).

  87. 87.

    & Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy. Eur. Thyroid J. 1, 176–185 (2012).

  88. 88.

    , , & Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin. Endocrinol. 68, 814–820 (2008).

  89. 89.

    & Experience in the use of radioactive iodine therapy for hyperthyroidism in Nigerian patients. A study of twenty-two patients. West Afr. J. Med. 22, 324–328 (2003).

  90. 90.

    , , , & Effect of inadequate iodine status in UK pregnant women on cognitive outcomes in their children: results from the Avon Longitudinal Study of Parents and Children (ALSPAC). Lancet 382, 331–337 (2013).

  91. 91.

    , , & Therapy of endocrine disease: Impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. Eur. J. Endocrinol. 170, R1–R15 (2014).

  92. 92.

    et al. Iodine status of UK schoolgirls: a cross-sectional survey. Lancet 377, 2007–2012 (2011).

  93. 93.

    , , & Iodine status of UK women of childbearing age. J. Hum. Nutr. Dietet. 21, 379–380 (2008).

  94. 94.

    et al. Perchlorate and thiocyanate exposure and thyroid function in first-trimester pregnant women. J. Clin. Endocrinol. Metab. 95, 3207–3215 (2010).

  95. 95.

    & Iodine deficiency in the UK and Ireland. Lancet 372, 888 (2008).

  96. 96.

    Iodine deficiency in Europe anno 2002. Thyroid Int. 5, 3–18 (2002).

  97. 97.

    et al. Iodine status assessment in Campania (Italy) as determined by urinary iodine excretion. Nutrition 25, 926–929 (2009).

  98. 98.

    , , , & Europe is iodine deficient. Lancet 361, 1226 (2003).

  99. 99.

    , & Global iodine nutrition: where do we stand in 2013? Thyroid 23, 523–528 (2013).

  100. 100.

    , , , & Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin. Endocrinol. 34, 77–83 (1991).

  101. 101.

    et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 292, 2591–2599 (2004).

  102. 102.

    , & Changes in the prevalence of hypothyroidism: the HUNT Study in Norway. Eur. J. Endocrinol. 169, 613–620 (2013).

  103. 103.

    , , & The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin. Endocrinol. 69, 687–696 (2008).

  104. 104.

    , , & The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000).

  105. 105.

    , , , & The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J. Clin. Endocrinol. Metab. 89, 3879–3884 (2004).

  106. 106.

    et al. Population-based national prevalence of thyroid dysfunction in Spain and associated factors: Di@bet.es study. Thyroid 27, 156–166 (2017).

  107. 107.

    , , , & Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5-year follow-up: the Japanese-Brazilian thyroid study. Eur. J. Endocrinol. 162, 569–577 (2010).

  108. 108.

    et al. Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters. Thyroid 19, 937–944 (2009).

  109. 109.

    et al. The epidemiology of thyroid diseases in the Arab world: a systematic review. J. Public Health Epidemiol. 8, 17–26 (2016).

  110. 110.

    et al. Natural course of euthyroidism and clues for early diagnosis of thyroid dysfunction: Tehran Thyroid Study. Thyroid 27, 616–625 (2017).

  111. 111.

    et al. The prevalence, incidence and natural course of positive antithyroperoxidase antibodies in a population-based study: Tehran Thyroid Study. PLOS ONE 12, e0169283 (2017).

  112. 112.

    , , , & The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin. Endocrinol. 51, 361–367 (1999).

  113. 113.

    , , , & Prevalence of thyroid antibodies in Nigerian patients. QJM 100, 107–112 (2007).

  114. 114.

    et al. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int. J. Tuberculosis Lung Dis. 16, 468–472 (2012).

  115. 115.

    et al. Drug-induced hypothyroidism during anti-tuberculosis treatment of multidrug-resistant tuberculosis: notes from the field. J. Tuberculosis Res. 4, 105–110 (2016).

  116. 116.

    et al. Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: a cross-sectional study in 10 cities. Thyroid 26, 1125–1130 (2016).

  117. 117.

    et al. Effect of iodine intake on thyroid diseases in China. N. Engl. J. Med. 354, 2783–2793 (2006).

  118. 118.

    et al. Prevalence of hypothyroidism in adults: an epidemiological study in eight cities of India. Indian J. Endocrinol. Metab. 17, 647–652 (2013).

  119. 119.

    Hypothyroidism in India: more to be done. Lancet Diabetes Endocrinol. 2, 778 (2014).

  120. 120.

    , , , & Thyroid function in pregnancy: what is normal? Clin. Chem. 61, 704–713 (2015).

  121. 121.

    , , & Should all women be screened for thyroid dysfunction in pregnancy? Womens Health 11, 295–307 (2015).

  122. 122.

    , & Thyroid function and human reproductive health. Endocr. Rev. 31, 702–755 (2010).

  123. 123.

    et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21, 1081–1125 (2011).

  124. 124.

    , , , & Patients with subclinical hypothyroidism before 20 weeks of pregnancy have a higher risk of miscarriage: a systematic review and meta-analysis. PLOS ONE 12, e0175708 (2017).

  125. 125.

    et al. Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery: the generation R study. J. Clin. Endocrinol. Metab. 98, 4382–4390 (2013).

  126. 126.

    et al. Antenatal thyroid screening and childhood cognitive function. N. Engl. J. Med. 366, 493–501 (2012).

  127. 127.

    et al. Treatment of subclinical hypothyroidism or hypothyroxinemia in pregnancy. N. Engl. J. Med. 376, 815–825 (2017).

  128. 128.

    et al. Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. J. Clin. Endocrinol. Metab. 97, 1536–1546 (2012).

  129. 129.

    & Update on the management of congenital hypothyroidism. Horm. Res. 68 (Suppl. 5), 107–111 (2007).

  130. 130.

    Second International Conference on Neonatal Thyroid Screening: progress report. J. Pediatr. 102, 653–654 (1983).

  131. 131.

    et al. Etiology of increasing incidence of congenital hypothyroidism in New Zealand from 1993–2010. J. Clin. Endocrinol. Metab. 97, 3155–3160 (2012).

  132. 132.

    , , & Is the incidence of congenital hypothyroidism really increasing? A 20-year retrospective population-based study in Quebec. J. Clin. Endocrinol. Metab. 96, 2422–2429 (2011).

  133. 133.

    & Screening for congenital hypothyroidism: a worldwide view of strategies. Best Pract. Res. Clin. Endocrinol. Metab. 28, 175–187 (2014).

  134. 134.

    & Drug-induced thyroid disorders. Drug Safety 13, 46–55 (1995).

  135. 135.

    et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann. Intern. Med. 101, 28–34 (1984).

  136. 136.

    , & Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management. Can. J. Neurol. Sci. 42, 284–291 (2015).

  137. 137.

    et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br. J. Cancer 99, 448–454 (2008).

  138. 138.

    , , & Iodine-Induced hypothyroidism. Thyroid 11, 501–510 (2001).

  139. 139.

    et al. Potential risks of excess iodine ingestion and exposure: statement by the american thyroid association public health committee. Thyroid 25, 145–146 (2015).

  140. 140.

    IGN. Iodine Global Network Annual Report 2016. IGN (2016).

  141. 141.

    , & Iodine nutrition: iodine content of iodized salt in the United States. Environ. Sci. Technol. 42, 1315–1323 (2008).

  142. 142.

    et al. Increased prevalence of thyroglobulin antibodies in Sri Lankan schoolgirls — is iodine the cause? Eur. J. Endocrinol. 143, 185–188 (2000).

  143. 143.

    , & The role of iodine in thyroid autoimmunity: from chickens to humans: a review. Autoimmunity 13, 61–68 (1992).

  144. 144.

    et al. Thyroglobulin epitope recognition in a post iodine-supplemented Sri Lankan population. Clin. Endocrinol. 59, 190–197 (2003).

  145. 145.

    et al. A cautious iodization program bringing iodine intake to a low recommended level is associated with an increase in the prevalence of thyroid autoantibodies in the population. Clin. Endocrinol. 75, 120–126 (2011).

  146. 146.

    et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J. Clin. Endocrinol. Metab. 92, 3122–3127 (2007).

  147. 147.

    , & Disturbances of thyroid function in adult population of the city of Cracow followed up for ten years observation [Polish]. Przegl. Lek. 62, 676–679 (2005).

  148. 148.

    et al. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J. Clin. Endocrinol. Metab. 83, 765–769 (1998).

  149. 149.

    , , , & Association between dietary iodine intake and prevalence of subclinical hypothyroidism in the coastal regions of Japan. J. Clin. Endocrinol. Metab. 78, 393–397 (1994).

  150. 150.

    , , , & Temporal trends in thyroid-stimulating hormone (TSH) and thyroid peroxidase antibody (ATPO) testing across two phases of iodine fortification in Tasmania (1995–2013). Clin. Endocrinol. 87, 386–393 (2017).

  151. 151.

    , , & Effects of long term iodized table salt consumption on serum T3, T4 and TSH in an iodine deficient area of Bangladesh. Mymensingh Med. J. 16, 57–60 (2007).

  152. 152.

    , , & Trends of thyroid function and autoimmunity to 5 years after the introduction of mandatory iodization in Italy. Eur. Ann. Allergy Clin. Immunol. 48, 77–81 (2016).

  153. 153.

    , , , & Iodine-induced thyrotoxicosis in Kivu, Zaire. Lancet 347, 552–553 (1996).

  154. 154.

    et al. Increase in thyrotoxicosis associated with iodine supplements in Zimbabwe. Lancet 346, 1563–1564 (1995).

  155. 155.

    An increase in thyrotoxicosis in southern Tasmania after an increase in dietary iodine. Med. J. Aust. 1, 1268–1271 (1971).

  156. 156.

    et al. The effects of different doses of oral iodized oil on goiter size, urinary iodine, and thyroid-related hormones. J. Clin. Endocrinol. Metab. 80, 891–897 (1995).

  157. 157.

    Iodisation in displaced African populations. Lancet 373, 214 (2009).

  158. 158.

    et al. Development of thyroid dysfunction among women with excessive iodine intake — a 3-year follow-up. J. Trace Elem. Med. Biol. 31, 61–66 (2015).

  159. 159.

    et al. Reference range of thyroid hormones in healthy school-age children: country-wide data from India. Clin. Biochem. 43, 51–56 (2010).

  160. 160.

    et al. Whole-genome sequence-based analysis of thyroid function. Nat. Commun. 6, 5681 (2015).

  161. 161.

    et al. The association of thyroid peroxidase antibody risk loci with susceptibility to and phenotype of Graves' disease. Clin. Endocrinol. 83, 556–562 (2015).

  162. 162.

    et al. Serum thyrotropin measurements in the community. Five-year follow-up in a large network of primary care physicians. Arch. Intern. Med. 167, 1533–1538 (2007).

  163. 163.

    et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N. Engl. J. Med. 376, 2534–2544 (2017).

  164. 164.

    et al. Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. J. Clin. Endocrinol. Metab. 99, 3353–3362 (2014).

  165. 165.

    & Subclinical thyroid disease. Lancet 379, 1142–1154 (2012).

  166. 166.

    , , & Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range. J. Clin. Endocrinol. Metab. 98, 3562–3571 (2013).

  167. 167.

    et al. Subclinical thyroid dysfunction and the risk of cognitive decline: a meta-analysis of prospective cohort studies. J. Clin. Endocrinol. Metab. 101, 4945–4954 (2016).

  168. 168.

    , , , & Thyroxine replacement: a clinical endocrinologist's viewpoint. Ann. Clin. Biochem. 53, 421–433 (2016).

  169. 169.

    IGN Iodine Global Network. IGN (2018).

  170. 170.

    in Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text (ed. Utiger, R. D. & Braverman, L. E.) 398–496 (JB Lippincott-Raven, 2005).

  171. 171.

    et al. A genetic risk score for thyroid peroxidase antibodies associates with clinical thyroid disease in community-based populations. J. Clin. Endocrinol. Metab. 100, E799–E807 (2015).

  172. 172.

    , , , & Role of genetic and non-genetic factors in the etiology of Graves' disease. J. Endocrinol. Invest. 38, 283–294 (2015).

  173. 173.

    & Smoking and risk of Graves' disease. JAMA 269, 479–482 (1993).

  174. 174.

    , , , & Thyroid-stimulating hormone-receptor antibody and thyroid hormone concentrations in smokers versus nonsmokers with Graves disease treated with carbimazole. JAMA 301, 162–164 (2009).

  175. 175.

    , , , & Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin. Endocrinol. 59, 396–401 (2003).

  176. 176.

    , , & Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 89, 6077–6086 (2004).

  177. 177.

    , , & Tobacco smoking and thyroid function: a population-based study. Arch. Intern. Med. 167, 1428–1432 (2007).

  178. 178.

    et al. Moderate alcohol consumption may protect against overt autoimmune hypothyroidism: a population-based case–control study. Eur. J. Endocrinol. 167, 483–490 (2012).

  179. 179.

    & Infection, thyroid disease, and autoimmunity. Endocr. Rev. 14, 107–120 (1993).

  180. 180.

    & The epidemiology of thyrotoxicosis in Denmark. Incidence and geographical variation in the Funen region 1972–1974. Acta Med. Scand. 208, 183–186 (1980).

  181. 181.

    , & Total and age-specific incidence of Graves' thyrotoxicosis, toxic nodular goitre and solitary toxic adenoma in Malmo 1970–1974. J. Intern. Med. 227, 137–141 (1990).

  182. 182.

    et al. Incidence of different forms of thyroid dysfunction and its degrees in an iodine sufficient area. Thyroidology 6, 49–54 (1994).

  183. 183.

    et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 13, 803–810 (2003).

  184. 184.

    et al. Investigations of thyroid hormones and antibodies based on a community health survey: the Busselton thyroid study. Clin. Endocrinol. 64, 97–104 (2006).

  185. 185.

    et al. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). Clin. Endocrinol. 68, 311–316 (2008).

  186. 186.

    et al. Undiagnosed thyroid dysfunction, thyroid antibodies, and iodine excretion in a Mediterranean population. Endocr 38, 391–396 (2010).

  187. 187.

    , , , & The incidence of thyroid function abnormalities & natural course of subclinical thyroid disorders, Tehran, I. R. Iran. J. Endocrinol. Invest. 35, 516–521 (2012).

  188. 188.

    et al. Reference ranges of serum TSH, FT4 and thyroid autoantibodies in the Thai population: the national health examination survey. Clin. Endocrinol. 80, 751–756 (2014).

  189. 189.

    et al. Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin. Chem. 52, 104–111 (2006).

  190. 190.

    et al. The evolution of thyroid function with puberty. Clin. Endocrinol. 76, 899–904 (2012).

  191. 191.

    , , & Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. Thyroid 9, 33–38 (1999).

  192. 192.

    , , & Increased incidence of thyrotoxicosis after iodine supplementation in an iodine sufficient area. J. Endocrinol. Invest. 17, 23–27 (1994).

  193. 193.

    et al. Epidemiological survey on the relationship between different iodine intakes and the prevalence of hyperthyroidism. Eur. J. Endocrinol. 146, 613–618 (2002).

  194. 194.

    et al. Increased prevalence of hyperthyroidism as an early and transient side-effect of implementing iodine prophylaxis. Public Health Nutr. 10, 799–802 (2007).

  195. 195.

    , & Goiter rate, serum thyrotropin, thyroid autoantibodies and urinary iodine concentration in Tehranian adults before and after national salt iodization. J. Endocrinol. Invest. 30, 404–410 (2007).

  196. 196.

    et al. Doubling in the use of thyroid hormone replacement therapy in Denmark: association to iodization of salt? Eur. J. Epidemiol. 26, 629–635 (2011).

  197. 197.

    et al. The effect of voluntary iodine prophylaxis in a small rural community: the Pescopagano survey 15 years later. J. Clin. Endocrinol. Metab. 98, 1031–1039 (2013).

Download references

Author information

Author notes

    • Peter N. Taylor
    • , Diana Albrecht
    •  & Anna Scholz

    These authors contributed equally: Peter N. Taylor, Diana Albrecht and Anna Scholz.

Affiliations

  1. Thyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.

    • Peter N. Taylor
    • , Anna Scholz
    • , John H. Lazarus
    • , Colin M. Dayan
    •  & Onyebuchi E. Okosieme
  2. University Medicine Greifswald, Institute for Community Medicine, Greifswald, Germany.

    • Diana Albrecht
  3. Clinica Universidad de Navarra, Department of Endocrinology and Nutrition, Pamplona, Spain.

    • Gala Gutierrez-Buey

Authors

  1. Search for Peter N. Taylor in:

  2. Search for Diana Albrecht in:

  3. Search for Anna Scholz in:

  4. Search for Gala Gutierrez-Buey in:

  5. Search for John H. Lazarus in:

  6. Search for Colin M. Dayan in:

  7. Search for Onyebuchi E. Okosieme in:

Contributions

P.N.T., D.A., A.S., G.G. and O.E.O. researched data for the article, made substantial contributions to discussion of content, wrote the article and reviewed and/or edited the manuscript before submission. C.M.D. and J.H.L. made substantial contributions to discussion of content and reviewed and/or edited the manuscript before submission.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Peter N. Taylor.

Glossary

Thyrotoxicosis

The clinical state that results from too much thyroid hormone in the body. In the overwhelming majority of cases, this is due to excess production from the thyroid gland (hyperthyroidism).

Silent thyroiditis

A self-limiting subacute disorder that results in temporary hyperthyroidism, usually followed by a brief period of hypothyroidism and then recovery of normal thyroid function. It most commonly occurs in females in the post-partum period.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrendo.2018.18

Further reading